September 11, 2008Cell Genesys: FDA places partial clinical hold on GVAX Phase 3 program - Forbes Cell Genesys: FDA places partial clinical hold on GVAX Phase 3 program - Forbes
BOSTON (Thomson Financial) - Cell Genesys Inc. Thursday said the Food and Drug Administration has placed a partial clinical hold on the GVAX Phase 3 program for prostate cancer as a result of the company's announcement to terminate the VITAL-2 Phase Source: www.forbes.com A Pfizer Drug With a Cloudy Future - The Money Times A cautious recommendation for approval is better than nothing. But don't bet the farm on it. On Monday, Pfizer (NYSE: PFE) and partner Ligand Pharmaceuticals (Nasdaq: LGND) received a positive vote from an FDA advisory panel committee for their Source: www.themoneytimes.com # posted by Network @ 8:00 AM
 |
Subscribe to Posts [Atom]